(1 - 25 from 29
)
Debiopharm Advances its Potent Wee1 Inhibitor into Clinical ...
www.almacgroup.com
Mar 5, — ... such as chemo- and radiation-therapies” explained Angela Zubel, Chief Development Officer, Research & Development, Debiopharm. › News Items
Debiopharm begins enrolment in CATRIPCA trial
www.clinicaltrialsarena.com
Oct 10, — Debiopharm chief development officer Dr Angela Zubel said: “This study is the third of a series of immuno-oncology studies investigating the ... › news › debiophar...
Debiopharm's experimental drug gets US FDA Breakthrough ...
futuremedicineindia.com
Mar 5, — ... high-risk locally-advanced head and neck cancer remains an area of unmet medical need,” said Angela Zubel, chief development officer, ... › news › debiopharms-...
FDA grants breakthrough therapy designation to Debio
www.healio.com
Feb 28, — ... remains an area of unmet medical need,” Angela Zubel, chief development officer of Debiopharm, said in a company-issued press release. › news › hematology-oncology
sorted by relevance / date